Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE DE MAUREPAS : revenue, balance sheet and financial ratios

SELARL PHARMACIE DE MAUREPAS is a French company founded 11 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in RENNES (35700), this company of category PME shows in 2024 a net income positive of 82 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE DE MAUREPAS (SIREN 809192685)
Indicator 2024 2022 2021 2020 2019 2018 2017
Revenue N/C N/C N/C N/C N/C N/C N/C
Net income 81 993 € 119 480 € 85 200 € 124 337 € -51 937 € 34 045 € 29 501 €
EBITDA N/C N/C N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2024, SELARL PHARMACIE DE MAUREPAS generates positive net income of 82 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 30 k€ -> 82 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

81 993 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 166%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 33%. The balance between equity and debt is satisfactory.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

165.824%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

33.107%

Solvency indicators evolution
SELARL PHARMACIE DE MAUREPAS

Sector positioning

Debt ratio
165.82 2024
2021
2022
2024
Q1: 16.45
Med: 58.41
Q3: 154.59
Average

In 2024, the debt ratio of SELARL PHARMACIE DE MAUREPAS (165.82) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
33.11% 2024
2021
2022
2024
Q1: 28.92%
Med: 49.95%
Q3: 69.49%
Average +5 pts over 3 years

In 2024, the financial autonomy of SELARL PHARMACIE DE MAUREPAS (33.1%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Positioning of SELARL PHARMACIE DE MAUREPAS in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of SELARL PHARMACIE DE MAUREPAS is estimated at 1 144 682 € (range 797 139€ - 1 712 511€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
797k€ 1144k€ 1712k€
1 144 682 € Range: 797 139€ - 1 712 511€
NAF 5 année 2024

Valuation method used

Net Income Multiple
81 993 € × 14.0x = 1 144 683 €
Range: 797 139€ - 1 712 511€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE DE MAUREPAS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE DE MAUREPAS

What is the revenue of SELARL PHARMACIE DE MAUREPAS ?

The revenue of SELARL PHARMACIE DE MAUREPAS is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL PHARMACIE DE MAUREPAS profitable?

Yes, SELARL PHARMACIE DE MAUREPAS generated a net profit of 82 k€ in 2024.

Where is the headquarters of SELARL PHARMACIE DE MAUREPAS ?

The headquarters of SELARL PHARMACIE DE MAUREPAS is located in RENNES (35700), in the department Ille-et-Vilaine.

Where to find the tax return of SELARL PHARMACIE DE MAUREPAS ?

The tax return of SELARL PHARMACIE DE MAUREPAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE DE MAUREPAS operate?

SELARL PHARMACIE DE MAUREPAS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.